4151:TSEKyowa Kirin Co., Ltd. Analysis

Kyowa Kirin trades at a forward P/E of 16.8, well below the industry average of 26.2, yet the DCF‑derived fair value of ¥502 is dramatically lower than the current price of ¥2,331, implying a near‑term overvaluation despite a respectable dividend yield of 3% and a sustainable payout ratio of 48%. The stock shows a bullish price trend above its 20‑day SMA (¥2,548) and 50‑day SMA (¥2,531) but the MACD is bearish and the RSI sits at 41.7, indicating limited upside momentum; the upside/downside estimate is –8.2%, and the market is in a “greed” phase (fear‑greed index 72.9). Volume is increasing, volatility is high at 76.6% over 30 days, while beta is low at 0.16, suggesting price swings are driven more by company‑specific news than market moves. Fundamentals reveal solid revenue growth of 11% YoY, a gross margin of 74%, operating margin of 28% and a cash pile of ¥218 bn with zero debt, but free cash flow is modest at ¥2 bn and ROE is only 7.7%, pointing to modest efficiency. Recent material news is mixed: management projects higher FY‑2026 revenue, yet the discontinuation of rocatinlimab trials and the termination of the Amgen partnership raise regulatory and pipeline execution concerns. Analyst consensus remains a “hold” with median target ¥2,000, below today’s price, reinforcing the view that the stock is currently priced for limited upside.